NU-GEMFIBROZIL CAP 300MG CAPSULE

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

GEMFIBROZIL

Dostupno od:

NU-PHARM INC

ATC koda:

C10AB04

INN (International ime):

GEMFIBROZIL

Doziranje:

300MG

Farmaceutski oblik:

CAPSULE

Sastav:

GEMFIBROZIL 300MG

Administracija rute:

ORAL

Jedinice u paketu:

100

Tip recepta:

Prescription

Područje terapije:

FRIBIC ACID DERIVATIVES

Proizvod sažetak:

Active ingredient group (AIG) number: 0116135001; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2012-09-04

Svojstava lijeka

PRODUCT MONOGRAPH
NU-GEMFIBROZIL
GEMFIBROZIL CAPSULES USP
300 MG
GEMFIBROZIL TABLETS USP
600 MG
ANTIHYPERLIPIDEMIC AGENT
NU
A
PHARM INC.
DATE OF PREPARATION:
50 MURAL STREET, UNITS 1 & 2
November 25, 1993
RICHMOND HILL, ONTARIO
DATE OF REVISION:
L4B 1E4
February 6, 2004
CONTROL# 089327
1
PRODUCT MONOGRAPH
NU-GEMFIBROZIL
Gemfibrozil Capsules USP
300 mg
Gemfibrozil Tablets USP
600 mg
THERAPEUTIC CLASSIFICATION
Antihyperlipidemic Agent
ACTIONS AND CLINICAL PHARMACOLOGY
Gemfibrozil is a lipid regulating agent which decreases serum
triglycerides and total cholesterol,
and increases high density lipoprotein cholesterol. The lipid-lowering
changes occur primarily in
the very low density lipoprotein (VLDL) fraction (S
f
0-20) rich in triglycerides and to a lesser extent
in the low density lipoprotein (LDL) fraction (S
f
20-400) rich in cholesterol. Gemfibrozil treatment
of patients with elevated triglycerides due to Type IV
hyperlipoproteinemia may cause a rise in
LDL-cholesterol. In addition, gemfibrozil increases the high density
lipoprotein (HDL) cholesterol
subfractions, HDL
2
and HDL
3
, as well as apolipoproteins Al and All.
Epidemiological studies have shown that both low HDL-cholesterol and
high LDL-cholesterol are
independent risk factors for coronary heart disease. Depending on the
type of hyperlipidemia,
pharmacological intervention with gemfibrozil raises HDL-cholesterol
and may lower LDL-
cholesterol, and may be associated with reduced morbidity due to
coronary heart disease as
reported in the Helsinki Heart Study, a 5-year primary prevention
Phase IV clinical trial.
The mechanism of action has not been definitely established. In man,
gemfibrozil has been
shown to inhibit peripheral lipolysis and to decrease the hepatic
extraction of free fatty acids, thus
reducing hepatic triglyceride production. Gemfibrozil also inhibits
the synthesis and increases
clearance of VLDL carrier apolipoprotein B, leading to a decrease in
VLDL.
2
Animal studies suggest that gemfibrozil may, in addition to elevating
HDL cholester